10 Best AI Penny Stocks To Buy After the AI Crash

Page 3 of 3

4. Rezolve AI (NASDAQ:RZLV)

Share Price as of November 18: $0.99

Stock Upside Potential as of November 18: 699.66%

Rezolve AI (NASDAQ:RZLV) could be an interesting speculative AI investment following the broader AI stock sell-off. That’s because the company offers investors exposure to the intersection of artificial intelligence, digital commerce, and retail technology.

The company is increasingly leveraging AI to transform how consumers discover products, interact with retailers, and complete purchases. It’s also targeting the commercial application of AI, where successful adoption could translate into recurring software revenue.

One of the strongest arguments for Rezolve AI is its reported revenue acceleration, which reached $130.8 million in the first half of 2026, up 1970%. Gross profit increased to $63.9 million from $6 million, helped by the customer base expanding to more than 1,640. Management reaffirmed full-year 2026 revenue guidance of approximately $360 million and annual recurring revenue of $500 million, underscoring expected commercial growth. Why is the revenue surge turning heads?

Rezolve AI has also inked strategic partnerships with major technology and consulting businesses, including Microsoft, Google, and Tata Consultancy, expected to support the growth.

On October 30, Titan Partners initiated coverage of the stock with a $5 price target amid growing confidence in underlying growth visible in the reported financial results.

3. BigBear.ai Holdings, Inc. (NYSE:BBAI)

Share Price as of November 18: $1.75

Stock Upside Potential as of November 18: 85.71%

BigBear.ai Holdings, Inc. (NYSE:BBAI) is one of the best AI penny stocks to consider after the AI crash, offering exposure to the growing market for artificial intelligence, defense technology, and government data analytics. While the stock is down about 58% year-to-date, its appeal lies in its focus on specialized AI applications rather than competing directly with major technology companies.

One of BigBear.ai Holdings, Inc.’s biggest competitive advantages is its exposure to the expanding defense and national security AI market. Its recent contract wins with the FBI, U.S. Coast Guard, and Department of Energy demonstrate its growing presence in these markets. BigBear.ai vs. Airship AI: which one offers better value?

BigBear.ai Holdings, Inc. secured more than 25 new contracts following its second-quarter results, representing over $225 million in contract value. Its backlog increased 22% sequentially to $330 million, asserting strong demand for the company’s AI-powered solutions.

Additionally, financial results suggest the underlying business is gaining momentum. In the third quarter of 2026, revenue increased 31% year over year to $43.6 million, while gross margin improved to 31.2%, up from 22.4% in the prior-year quarter. Importantly, management raised its full-year 2026 revenue guidance to between $150 million and $165 million, reflecting stronger business performance and growing demand for its AI solutions.

Meanwhile, Wall Street analysts remain cautiously optimistic about the company’s long-term prospects. On October 29, Northland reiterated its Market Performance rating on the stock but lowered the price target to $3.50 from $4, citing concerns about industry multiple compression. Earlier on October 28, Cantor Fitzgerald lowered its price target to $3 and kept the Neutral rating in response to the third-quarter results.

2. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Share Price as of November 18: $2.83

Stock Upside Potential as of November 18: 135.40%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a compelling AI penny stock at the intersection of artificial intelligence, biotechnology, and pharmaceutical research. The company is increasingly applying AI, machine learning, and automated laboratory technologies to accelerate drug discovery and development.

While the stock is down about 9% year to date, its long-term prospects remain intact as AI transforms pharmaceutical research. Its proprietary Recursion OS platform, which combines machine learning and advanced computing, is helping researchers identify disease-related biological patterns and discover potential drug targets.

Recursion Pharmaceuticals, Inc. is also leveraging AI to advance its pipeline. REC-4881, the company’s Phase 2 program targeting familial adenomatous polyposis (FAP), has already produced encouraging results, while its experimental cancer drug, REC-1245, has demonstrated two confirmed partial responses in endometrial cancer. Has Recursion entered a new growth phase?

Recursion Pharmaceuticals, Inc. reported $561.5 million in cash, cash equivalents, and restricted cash at the end of September, reducing the immediate pressure to raise additional capital. Consequently, it remains in a strong financial position to advance its pipeline.

Meanwhile, Wall Street is bullish about the company’s growth prospects. On October 16, Morgan Stanley raised its price target to $5.90 from $5.30. On October 15, Cathie Wood of ARK Investment bought 4.2 million shares of the company, affirming the bullish thesis on Wall Street.

1. Aurora Innovation, Inc. (NASDAQ:AUR)

Share Price as of November 18: $3.90

Stock Upside Potential as of November 18: 193.04%

Aurora Innovation, Inc. (NASDAQ:AUR) is an attractive AI penny stock to consider, offering exposure to artificial intelligence, autonomous driving, and the commercialization of self-driving trucks. The stock is already up about 20% year-to-date, outperforming the broader market.

The outperformance comes as the company increasingly works on an AI-powered autonomous driving platform designed to transform the transportation and logistics industries. The Aurora Driver platform combines AI software, sensors, computing hardware, and data to enable trucks to operate autonomously. Its long-term opportunity lies in reducing trucking costs, improving freight efficiency, and addressing driver shortages.

Aurora Innovation, Inc. has considerable financial resources to support its ambitious expansion plans. The company held approximately $1.03 billion in cash, cash equivalents, and short-term investments as of the end of September. This provides funding for research, fleet expansion, manufacturing, and commercialization. Explore Aurora Innovation’s autonomous vehicle opportunity.

Wall Street remains broadly optimistic, with Morgan Stanley maintaining a Buy rating on the stock and an $18 price target as of October 29. Canaccord Genuity also maintains a Buy rating and a $17 price target.

Partnerships, a growing driverless fleet, and more than $100 million in liquidity provide a foundation for pursuing commercial expansion. If Aurora Innovation, Inc. successfully scales its technology, secures additional customers, and improves its operating economics, the business could have considerable long-term growth potential.

READ NEXT: 10 Best Mid-Cap US Stocks to Buy Now and 10 Best Low Priced Technology Stocks to Invest In

Follow Insider Monkey on Google News.

Page 3 of 3